MiR-144-3p enhances cisplatin sensitivity in triple-negative breast cancer by targeting SLC7A11 to induce ferroptosis
Archives of Biochemistry and Biophysics · 2026-08 · 782 · 110882
DOI: 10.1016/j.abb.2026.110882 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2026-08. Verfasst von Rui Tian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Provincial Clinical…. Hauptthemen laut MEDLINE: MicroRNAs, Cisplatin, Ferroptosis, Amino Acid Transport System y+. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive subtype in which resistance to cisplatin (cis-diamminedichloroplatinum II, CDDP) limits therapeutic efficacy, and ferroptosis has emerged as a key determinant of chemotherapy response. This study investigated the role of miR-144-3p in regulating CDDP sensitivity in TNBC and its underlying mechanism. METHODS: MiR-144-3p expression was analyzed in TNBC tissues from CDDP-sensitive and -resistant patients. CDDP-resistant cell lines (MDA-MB-231/CDDP and BT-549/CDDP) were established by stepwise CDDP exposure and validated by increased IC50 values. Gain- and loss-of-function assays were performed using miR-144-3p mimic, si-SLC7A11, and SLC7A11 overexpression plasmids. Cell viability, clonogenic survival, and apoptosis were assessed by CCK-8, colony formation, and flow cytometry. Ferroptosis was evaluated by measuring lipid peroxidation (C11-BODIPY), ROS, GSH, Fe2+ levels, and GPX4 expression. Targeting of SLC7A11 by miR-144-3p was confirmed by dual-luciferase reporter assay and expression analysis. A xenograft model was used to assess tumor growth, SLC7A11 expression, and ferroptosis-related indicators in vivo. RESULTS: MiR-144-3p was significantly downregulated in CDDP-resistant TNBC tissues and cells. Its restoration enhanced CDDP sensitivity and was associated with increased ferroptotic features, as evidenced by increased lipid peroxidation and ROS, decreased GSH, elevated Fe2+ levels, and reduced GPX4 expression. Mechanistically, miR-144-3p directly targeted SLC7A11. Rescue experiments showed that SLC7A11 overexpression attenuated ferroptosis and partially reversed CDDP sensitization. In vivo, miR-144-3p overexpression suppressed tumor growth, reduced SLC7A11 expression, and enhanced ferroptotic features. CONCLUSION: Our findings suggest that miR-144-3p enhances CDDP sensitivity in TNBC, at least in part, through regulation of the SLC7A11-mediated ferroptosis pathway, identifying a novel regulatory axis with therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for…
Zitieren
APA
Tian, R., Yu, M., & Cheng, H. (2026). MiR-144-3p enhances cisplatin sensitivity in triple-negative breast cancer by targeting SLC7A11 to induce ferroptosis. Archives of Biochemistry and Biophysics, 782, 110882. https://doi.org/10.1016/j.abb.2026.110882
Vancouver
Tian R, Yu M, Cheng H. MiR-144-3p enhances cisplatin sensitivity in triple-negative breast cancer by targeting SLC7A11 to induce ferroptosis. Archives of Biochemistry and Biophysics. 2026;782:110882. doi:10.1016/j.abb.2026.110882
BibTeX
@article{Tian2026,
author = {Tian, Rui and Yu, Mancheng and Cheng, Hongtao},
title = {MiR-144-3p enhances cisplatin sensitivity in triple-negative breast cancer by targeting SLC7A11 to induce ferroptosis},
journal = {Archives of Biochemistry and Biophysics},
year = {2026},
volume = {782},
pages = {110882},
doi = {10.1016/j.abb.2026.110882}
}
EUVIMED